HEPION PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
HEPION PHARMACEUTICALS, INC. (HEPA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$48.93 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-16.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-04-16
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-12-31 was -$9.73M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was -$9.27M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was -$7.67M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-03-31 was -$6.06M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$48.93M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$45.34M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$32.72M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$20.36M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$48.93M 10-K · filed 2024-04-16 | |||
| 2022-12-31 | -$45.34M 10-K · filed 2024-04-16 | |||
| 2021-12-31 | -$9.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10 | -$18.99M derived: sum of 2 quarters · filed 2023-04-10 | -$26.66M derived: sum of 3 quarters · filed 2023-04-10 | -$32.72M 10-K · filed 2023-04-10 |
| 2021-09-30 | -$9.27M 10-Q · filed 2021-11-15 | -$16.93M derived: sum of 2 quarters · filed 2021-11-15 | -$23.00M 10-Q · filed 2021-11-15 | -$27.95M derived: sum of 4 quarters · filed 2022-04-08 |
| 2021-06-30 | -$7.67M 10-Q · filed 2021-08-16 | -$13.73M 10-Q · filed 2021-08-16 | -$18.68M derived: sum of 3 quarters · filed 2022-04-08 | -$24.92M derived: sum of 4 quarters · filed 2022-04-08 |
| 2021-03-31 | -$6.06M 10-Q · filed 2021-05-14 | -$11.02M derived: sum of 2 quarters · filed 2022-04-08 | -$17.26M derived: sum of 3 quarters · filed 2022-04-08 | -$22.20M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-12-31 | -$4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08 | -$11.19M derived: sum of 2 quarters · filed 2022-04-08 | -$16.13M derived: sum of 3 quarters · filed 2022-04-08 | -$20.36M 10-K · filed 2022-04-08 |
| 2020-09-30 | -$6.24M 10-Q · filed 2021-11-15 | -$11.18M derived: sum of 2 quarters · filed 2021-11-15 | -$15.40M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$4.94M 10-Q · filed 2021-08-16 | -$9.17M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$4.23M 10-Q · filed 2021-05-14 | |||
| 2018-12-31 | -$17.90M 10-K · filed 2019-03-14 | |||
| 2017-12-31 | -$7.51M 10-K · filed 2019-03-14 | |||
| 2017-06-30 | -$17.59M 10-K · filed 2019-03-14 | |||
| 2016-06-30 | -$17.00M 10-KT · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |